190 related articles for article (PubMed ID: 30076608)
1. Improving anticancer activity towards colon cancer cells with a new p53-activating agent.
Raimundo L; Espadinha M; Soares J; Loureiro JB; Alves MG; Santos MMM; Saraiva L
Br J Pharmacol; 2018 Oct; 175(20):3947-3962. PubMed ID: 30076608
[TBL] [Abstract][Full Text] [Related]
2. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
3. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
5. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
[TBL] [Abstract][Full Text] [Related]
7. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents.
Lemos A; Gomes AS; Loureiro JB; Brandão P; Palmeira A; Pinto MMM; Saraiva L; Sousa ME
Molecules; 2019 May; 24(10):. PubMed ID: 31121972
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells.
Gong EY; Shin YJ; Hwang IY; Kim JH; Kim SM; Moon JH; Shin JS; Lee DH; Hur DY; Jin DH; Hong SW; Lee WK; Lee WJ
Toxicol Lett; 2016 Sep; 258():126-133. PubMed ID: 27339904
[TBL] [Abstract][Full Text] [Related]
10. Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin.
Ravizza R; Gariboldi MB; Passarelli L; Monti E
BMC Cancer; 2004 Dec; 4():92. PubMed ID: 15601469
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
13. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
14. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M
World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
16. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
[TBL] [Abstract][Full Text] [Related]
17. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
18. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of p53 by adenovirus type 12 E1B-55K deregulates cell cycle control and sensitizes tumor cells to genotoxic agents.
Li Q; Zhao LY; Zheng Z; Yang H; Santiago A; Liao D
J Virol; 2011 Aug; 85(16):7976-88. PubMed ID: 21680522
[TBL] [Abstract][Full Text] [Related]
20. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.
Carvajal D; Tovar C; Yang H; Vu BT; Heimbrook DC; Vassilev LT
Cancer Res; 2005 Mar; 65(5):1918-24. PubMed ID: 15753391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
